About US
Contact us
-
New compounds may prevent spread of malariaResearchers at Imperial College London have discovered compounds that can potentially prevent malaria parasites from infecting mosquitoes, which could in turn avoid the spread of the disease to humans2018/9/21
-
Novo Nordisk to lay off 400 employees in Denmark and ChinaNovo Nordisk has announced plans to lay off around 400 staff in research and development (R&D) roles at its China and Denmark sites as part of its R&D restructuring strategy. The restructurin2018/9/21
-
NIAID and Children’s National boost paediatric clinical research allianceNational Institute of Allergy and Infectious Diseases (NIAID), a unit of the National Institutes of Health (NIH), has strengthened a clinical research partnership with the Children’s National Health S2018/9/20
-
Cancer Research UK launches new research hub for biotherapeuticsCancer Research UK has launched a global centre of excellence in London to facilitate research on biotherapeutics as a treatment option for cancer. The new Cancer Research UK City of London Centre ha2018/9/20
-
AstraZeneca’s Lumoxiti secures FDA nod to treat hairy cell leukaemiaAstraZeneca and its research and development arm MedImmune have obtained approval from the US Food and Drug Administration (FDA) for the use of Lumoxiti to treat adults with relapsed or refractory hai2018/9/19
-
CRISPR, ViaCyte team up to develop stem cell therapies for diabetesSwiss gene editing company CRISPR Therapeutics and US-based regenerative medicine firm ViaCyte have formed a strategic alliance to discover, develop and commercialise stem cell therapies for diabetes2018/9/19
-
EMA and FDA find additional impurity in valsartan productsThe European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have reported the presence of a second impurity in valsartan products. The new impurity is called N-Nitrosodiethylami2018/9/18
-
Allergan to buy neurotoxins firm Bonti for $195mAllergan has entered an agreement to acquire biotechnology company Bonti for an upfront payment of $195m along with other potentialcommercial milestone-based payments. Bonti primarily develops and co2018/9/18
-
NIH’s new initiative to boost cures for sickle cell diseaseThe National Institutes of Health (NIH) has launched a new initiative to expedite the development of genetic therapies to treat sickle cell disease. The Cure Sickle Cell Initiative will leverage new2018/9/17
-
Shire gets marketing clearance for Veyvondi in EuropeIrish biotechnology firm Shire has secured authorisation from the European Commission (EC) to market Veyvondi for the treatment of adults with von Willebrand disease (VWD). The drug is indicated for2018/9/17